Post by AIxBiotech

The EU5 launch model assumes things that do not exist in emerging markets. Structured reimbursement timelines. Published HTA criteria. Standardised payer processes you can navigate from precedent. Central pharmacy distribution you can forecast. In MENA, CEE, Southeast Asia, and Latin America, none of those assumptions hold. Our team at AIxBiotech has been watching biotech commercial teams struggle with this gap for years. The EU pharma reform package passed in 2024 is making it more urgent. More products, launched earlier, in more markets, with less analytical infrastructure to navigate them. IQVIA (https://lnkd.in/g68ea9e) data shows that emerging markets now represent over 30% of global pharma volume growth. L.E.K. Consulting (https://lnkd.in/euhkyYjX) research shows that the companies outperforming in these markets share one trait: they stopped applying EU5 launch logic and built market-specific intelligence infrastructure instead. AI is closing the gap. Predictive launch timing models trained on local registration precedents. Distributor scoring tools that flag reliability before you sign a contract. Real-time tender probability models for markets where public procurement drives 60% of sales. The commercial teams that will win in emerging markets over the next five years are not the ones with the biggest local headcount. They are the ones with the best data infrastructure for markets where data has never been easy to get. Based on publicly available information. This analysis covers non-proprietary, publicly disclosed data only. 🤖 AI x Biotech: No hype. Concrete signals for biotech executives and commercial teams. Follow @aixbiotech for daily updates — and to keep us going.